Professor Katie Ewer, lead of the second-generation malaria vaccine program at GlaxoSmithKline (GSK), highlighted recent advancements in malaria vaccine development while acknowledging the ongoing challenges in combating the disease. Speaking about her work, which began in 2008, Ewer described malaria as a complex and longstanding health threat that has required decades of research to tackle effectively.

Malaria, one of the oldest and deadliest diseases globally, continues to claim the life of a child every minute. Despite this grim reality, Ewer noted significant progress in the last few years, with two existing vaccines now being administered to tens of millions of children across more than 20 African countries. These vaccines primarily target the early stage of the malaria parasite’s life cycle, immediately following infection by mosquito bites.

Ewer emphasized that while these vaccines represent important breakthroughs, further innovation is needed. At GSK, she and her team are working on developing new vaccine candidates aimed at later stages of the parasite’s development, a phase when young children often suffer the most severe symptoms. This approach aims to provide an additional layer of protection against the disease.

Collaboration among leading scientists has been crucial in advancing malaria vaccine research, with UK-based researchers playing a central role. Ewer, who previously worked at the University of Oxford before joining GSK, pointed to the importance of this scientific synergy. She also noted that research efforts on malaria vaccines have had broader benefits, contributing to vaccine development for other diseases and thus providing public health advantages beyond malaria alone.

Despite the positive momentum, Ewer acknowledged that the path toward malaria elimination remains lengthy and complex. However, she expressed optimism about the recent breakthroughs and a strong commitment to ongoing research efforts.

The development and deployment of malaria vaccines mark an important milestone in the fight against a disease that has long resisted control. The continued focus on improving vaccine efficacy, especially by addressing different stages of the parasite, reflects a comprehensive strategy to reduce malaria’s global burden. As new vaccine candidates progress through early development, the scientific community remains vigilant in pursuit of solutions to protect vulnerable populations, particularly children in endemic regions.